Vakaramoko Diaby to Treatment Outcome
This is a "connection" page, showing publications Vakaramoko Diaby has written about Treatment Outcome.
Connection Strength
0.667
-
Nkemdirim Okere A, Sanogo V, Balkrishnan R, Diaby V. A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2020 Sep; 29(9):105053.
Score: 0.141
-
Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, Diaby V. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. Cancer Med. 2019 01; 8(1):117-127.
Score: 0.127
-
Okere AN, Ezendu K, Berthe A, Diaby V. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. J Manag Care Spec Pharm. 2018 Feb; 24(2):142-152.
Score: 0.119
-
Okere AN, Montesdeoca J, Glasper A, Diaby V. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review. Curr Diabetes Rev. 2018; 14(4):363-375.
Score: 0.119
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
Score: 0.093
-
Wang CY, Pham PN, Kim S, Lingineni K, Schmidt S, Diaby V, Brown J. Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States. Clin Transl Sci. 2020 03; 13(2):352-361.
Score: 0.034
-
Limdi NA, Cavallari LH, Lee CR, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshees AL, Empey PE, Duarte JD, Diaby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 10; 20(5):724-735.
Score: 0.034